BioCryst Pharmaceuticals, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $0.14 | $0.30 | +114.3% | Beat |
| Q12026 FY2026 | $0.06 | $-0.03 | -150.0% | Miss |
| Q42025 FY2025 | $0.07 | $1.12 | +1500.0% | Beat |
Back to BCRX overview · BCRX holders · BCRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.